The protective effect of boric acid on cholestatic rat liver ischemia reperfusion injury

SERKAN GÜLER
ARİF ASLANER
HAMİT YAŞAR ELLİDAĞ
ŞENAY YILDIRIM
TUĞRUL ÇAKIR

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
GÜLER, SERKAN; ASLANER, ARİF; ELLİDAĞ, HAMİT YAŞAR; YILDIRIM, ŞENAY; and ÇAKIR, TUĞRUL (2021) "The protective effect of boric acid on cholestatic rat liver ischemia reperfusion injury," Turkish Journal of Medical Sciences: Vol. 51: No. 5, Article 61. https://doi.org/10.3906/sag-2101-153
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss5/61

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
The protective effect of boric acid on cholestatic rat liver ischemia reperfusion injury

Serkan GÜLER1, Arif ASLANER1*, Hamit Yaşar ELLİDAĞ2, Şenay YILDIRIM3, Tuğrul ÇAKIR1

1. Department of General Surgery, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey
2. Department of Biochemistry, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey
3. Department of Pathology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey

Background/aim: To evaluate the potential protective effects of boric acid (BA) in experimental cholestatic liver ischemia reperfusion (IR) injury model.

Materials and methods: The study included 24 female rats which were divided into 3 groups each containing 8 rats. The control group (Group 1) only received laparotomy. In the IR group (Group 2) biliary tract ligation was applied and 1 week later 45 min ischemia and 1 h reperfusion with relaparotomy without any treatment was implemented. In the treatment BA+IR group (Group 3). 1 week after the biliary ligation intraperitoneal administration of 200 mg/kg BA was given 10 min before the ischemia for 45 min and reperfusion for 1 h with relaparotomy. Liver tissue and blood samples were taken for histopathological and biochemical examination. Ischemia modified albumin (IMA), SCUBE1, total antioxidant status (TAS), and total oxidant status (TOS) levels were also examined.

Results: Compared to control, groups IR and BA+IR had higher serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total, and direct bilirubin levels. Albumin value was high in the control group and low in the other groups. In terms of IMA levels there was no significant difference between groups (p > 0.05). When SCUBE-1 levels were examined groups IR and BA+IR were significantly higher than the group 1. TAS was highest in the group BA+IR whereas TOS was highest in the group IR and lower in the group BA+IR. In histopathological analysis, loss of intercellular border loss in hepatocytes, diffuse nuclear pycnosis and mild to moderate neutrophilic cell infiltration were observed in the IR group. Statistically significant dissociation, hemorrhage and severe neutrophilic cell infiltration were seen in hepatocytes of rats with IR (p < 0.05).

Conclusion: BA has promising results in the treatment of experimental IR injury of the cholestatic liver because of its antioxidant effects. It may be used in clinical practice after more extensive studies about the effects of BA on IR injury of the cholestatic liver.

Key words: Boric acid, liver, cholestasis, ischemia reperfusion

Received: 13.01.2021 • Accepted/Published Online: 09.05.2021 • Final Version: 21.10.2021

Background/aim: To evaluate the potential protective effects of boric acid (BA) in experimental cholestatic liver ischemia reperfusion (IR) injury model.

Materials and methods: The study included 24 female rats which were divided into 3 groups each containing 8 rats. The control group (Group 1) only received laparotomy. In the IR group (Group 2) biliary tract ligation was applied and 1 week later 45 min ischemia and 1 h reperfusion with relaparotomy without any treatment was implemented. In the treatment BA+IR group (Group 3). 1 week after the biliary ligation intraperitoneal administration of 200 mg/kg BA was given 10 min before the ischemia for 45 min and reperfusion for 1 h with relaparotomy. Liver tissue and blood samples were taken for histopathological and biochemical examination. Ischemia modified albumin (IMA), SCUBE1, total antioxidant status (TAS), and total oxidant status (TOS) levels were also examined.

Results: Compared to control, groups IR and BA+IR had higher serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total, and direct bilirubin levels. Albumin value was high in the control group and low in the other groups. In terms of IMA levels there was no significant difference between groups (p > 0.05). When SCUBE-1 levels were examined groups IR and BA+IR were significantly higher than the group 1. TAS was highest in the group BA+IR whereas TOS was highest in the group IR and lower in the group BA+IR. In histopathological analysis, loss of intercellular border loss in hepatocytes, diffuse nuclear pycnosis and mild to moderate neutrophilic cell infiltration were observed in the IR group. Statistically significant dissociation, hemorrhage and severe neutrophilic cell infiltration were seen in hepatocytes of rats with IR (p < 0.05).

Conclusion: BA has promising results in the treatment of experimental IR injury of the cholestatic liver because of its antioxidant effects. It may be used in clinical practice after more extensive studies about the effects of BA on IR injury of the cholestatic liver.

Key words: Boric acid, liver, cholestasis, ischemia reperfusion

1. Introduction

Ischemia is defined as the interruption or reduction of blood flow to the tissue for any reason. Reperfusion is defined as the normalization of blood flow in ischemic tissue. IR injury is the damage caused by free oxygen radicals (FOR) caused by reperfusion and reperfusion in order to maintain the viability of the tissue [1].

Trauma, shock, liver surgery and transplantation are among the most common causes of liver IR injury in the clinic [2]. Many mechanisms have been described regarding the mechanism of IR injury. As a result of the change in mitochondrial oxidative phosphorylation decrease in ATP increase in intracellular calcium and activation of proteases and phosphatases leading to the deterioration of cytoskeleton and membrane phospholipids excessive FOR is formed and causes oxidative stress [3,4].

In the presence of cholestasis, the liver is more susceptible to reperfusion damage [5,6]. When bile flow is interrupted sinusoidal endothelial cell damage accelerates; neutrophil accumulation and kupffer cell activation are stimulated [6]. Activated neutrophils and kupffer cells are the most important sources of reactive oxygen radicals in oxidative stress [7,8]. Cholestasis is a common finding in liver and pancreatic diseases requiring major hepatic surgery; therefore, cholestatic IR models are more valuable to reflect this situation.

IMA is an albumin that changes its structure as a result of ischemia reperfusion injury. In addition to ischemia, IMA may increase in acute coronary syndrome, cerebrovascular diseases, liver failure, end-stage renal disease, severe traumas, pulmonary embolism, sepsis, diabetes, systemic sclerosis, some neoplastic diseases, and
infections. In this way, we believe IMA is more clinically valuable.

Boron or boric acid (BA) is an element found in nature and is abundant in Turkey. Studies on its clinical use are quite common. BA has an inhibitory effect on peptidases, xanthine oxidase, nitric acid synthase, cytochrome b reductase. In addition, it also affects calcium, phosphorus, magnesium ion levels and vitamin D, insulin, testosterone, estrogen, and glucose metabolism [9,10]. It has been shown in many studies to have antioxidant and antiinflammatory effects [11–14].

The aim of this experimental study was to investigate the effects of BA on experimental IR injury of the cholestatic liver through the evaluation of oxidative stress and histopathological changes. To the best of our knowledge this is the first study in the literature to have examined the effect of BA on cholestatic liver damage caused by IR.

2. Materials and methods
The approval for this study was granted by the Animal Research Ethics Committee of Antalya Akdeniz University dated 15.01.2019 and numbered B.30.2.AKD.0.05.07.00/7. All procedures were applied at Akdeniz University Experimental Medicine and Animal Laboratory in accordance with the principles of the National Guidelines for Experimental Use of Laboratory Animals between January and March 2019.

2.1. Animals
In this study 24 female Wistar Albino rats weighing between 200–250 g were used. During both preoperative and postoperative periods, the rats were housed at cages with constant environmental conditions (temperature: 23 °C and humidity: 55.5%) and fed with standard laboratory feed and tap water. Access to food was stopped 12 h before anesthesia and to water 2 h prior to anesthesia.

2.2. Surgery and experimental protocol
This research aimed to investigate the effects of BA on IR injury of the cholestatic liver. The rats were randomized into 3 groups:

Group 1 (Control): Only laparotomy was performed. After waiting for 1 h and 45 min blood and tissue samples were taken and the animals were sacrificed. No other treatment was given.

Group 2 (IR): After laparotomy the common bile duct was dissected from adjacent tissue and ligated with 3/0 silk sutures. After the procedures each abdominal incision was closed with 3/0 prolene sutures. Subsequently the rats were allowed to feed. On the postoperative 7th day 200 mg/kg BA was given intraperitoneally. After waiting for 10 min relaparotomy was performed. The portal vein and hepatic artery were clamped and ischemia was performed for 45 min. Reperfusion was performed for 1 h by opening the clamp. Liver tissue samples and blood samples from the aorta were taken for histopathological and biochemical analyses and the rats were sacrificed.

Group 3 (BA+IR): After laparotomy the common bile duct was found and dissected from adjacent tissues and ligated with 3/0 silk sutures. After the procedures each abdominal incision was closed with 3/0 prolene sutures. Subsequently the rats were allowed to feed. On the postoperative 7th day 200 mg/kg BA was given intraperitoneally. After waiting for 10 min relaparotomy was performed. The portal vein and hepatic artery were clamped and ischemia was performed for 45 min. Reperfusion was performed for 1 h by opening the clamp. Liver tissue samples and blood samples from the aorta were taken for histopathological and biochemical analyses and the rats were sacrificed.

2.3. Biochemical analysis
Routine parameters:

- Rat serum albumin (Beckman Coulter Diagnostics, Brea, CA, USA; catalogue no. OSR6602), alanine aminotransferase (ALT) (Beckman Coulter Diagnostics, Brea, CA, USA; catalogue no. OSR6607), aspartate aminotransferase (AST) (Beckman Coulter Diagnostics, Brea, CA, USA; catalogue no. OSR6504), total bilirubin (TBIL) (Beckman Coulter Diagnostics, Brea, CA, USA; catalogue no. OSR6512), and direct bilirubin (DBIL) (Beckman Coulter Diagnostics, Brea, CA, USA; catalogue no. OSR6511) levels were determined using an autoanalyzer (Beckman AU5800; Beckman Coulter Diagnostics, Brea, CA, USA).

2.4. Measurement of SCUBE1
Rat serum SCUBE1 levels were quantified using a commercially available ELISA kit (Bioassay Technology Laboratory, Shanghai, China; catalogue no. E0948Ra) according to the manufacturer’s instructions. The sensitivity of the assay was 0.35 ng/mL with inter- and intra-assay coefficients of variation of <10%. Assay results were expressed as ng/mL.

2.5. Measurement of ischemia modified albumin (IMA)
Reduced cobalt–albumin-binding capacity (IMA level) was measured using the rapid and colorimetric method developed by Bar-Or et al. [15]. Briefly 200 μL rat serum was transferred into glass tubes and 50 μL 0.1% CoCl₂·6H₂O (lot S38901-248. Sigma Aldrich, St Louis, MO, USA) was added. After gentle shaking the mixture incubated for 10 min to ensure sufficient cobalt–albumin binding. Then 50 μL 1.5 mg/mL dithiothreitol (DTT) (lot D5545-1G. Sigma-Aldrich) was added as a coloring agent. After 2 min 1 mL 0.9% NaCl was added to halt the binding between cobalt and albumin. A blank was prepared for every specimen: at the DTT addition step. Fifty microliters of distilled water was used instead of 50 μL 1.5 mg/mL DTT
to obtain a blank without DTT. The absorbances were recorded at 470 nm with a spectrophotometer (UV1201. Shimadzu, Kyoto, Japan). Color formation in specimens with DTT was compared with color formation in the blank tubes and the results are expressed as absorbance units.

2.6. Measurement of serum total oxidant status (TOS)
Serum TOS levels were analyzed using an automated colorimetric measurement method developed by Erel [16]. In this method oxidants in the sample oxidize the ferrous ion-chelated complex to ferric ion, which makes a colored complex with a chromogenic in an acidic medium. The color intensity which can be measured spectrophotometry is related to the total amount of oxidant molecules present in the sample. The results are expressed in terms of micro molar hydrogen peroxide equivalent per liter (μmol H$_2$O$_2$ equiv./l).

2.7. Measurement of serum total antioxidant status (TAS)
Serum TAS levels were analyzed using an automated colorimetric measurement method developed by Erel [17]. In this method antioxidants in the sample reduce dark blue-green colored 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) radicals to a colorless reduced ABTS form. The change of absorbance at 660 nm is related to the total antioxidant level in the sample. This method determines the antioxidative effect of the sample against the potent free radical reactions initiated by the produced hydroxyl radical. The results are expressed as micro molar Trolox equivalent per liter (μmol Trolox equiv./l).

2.8. Oxidative stress index (OSI)
The percentage ratio of the TOS level to the TAS level is given as the OSI [18]. For calculation the resulting micro molar unit of TAS was changed to mmol/L and the OSI value was calculated according to the following formula: OSI (arbitrary unit) = TOS (μmol H$_2$O$_2$ equiv./l)/TAS (μmol Trolox equiv./l).

2.9. Histopathological evaluation
Liver samples were fixed in 10% neutral formalin solution. After 48 h of fixation tissues were dehydrated through a series of graded alcohol embedded in paraffin and cut into 4 μm sections using a microtome (Leica RM 2125. Leica Microsystems Nussloch GmbH. Germany) and stained with hematoxylin and eosin (H&E). These preparations were blindly evaluated by the pathologist under a light microscope.

Hepatic injury was evaluated for severity of hepatic injury using an ordinal scale as follows: Grade 0 = Minimal or no evidence of injury; Grade 1 = Mild injury with cytoplasmic vacuolation and focal nuclear pycnosis; Grade 2 = Moderate to severe injury with nuclear pycnosis, cytoplasmic hypereosinophilia and loss of intercellular borders; Grade 3 = Severe necrosis with disintegration of hepatic cords, hemorrhage and neutrophil infiltration [19].

2.10. Statistical analysis
The data obtained after the study were evaluated statistically using the SPSS package program (IBM Corp., SPSS Statistics for Windows, v. 22.0. Armonk, NY, USA). Mean, median, standard deviation, and frequency values were used in the descriptive statistics of the data. Three groups were analyzed using the nonparametric Kruskal–Wallis test. Mann–Whitney-U test was used for paired comparisons in subgroup analysis. A p value of < 0.05 was considered significant.

3. Results
Serum ALT, AST, ALP, LDH, total, and direct bilirubin levels were low in the control group while it was higher in the IR and BA+IR group (p < 0.01). There was no statistically significant difference between these two groups. In terms of albumin values, albumin values of the control group were higher, but there was no difference between the IR group and the BA+IR group (Table).

For SCUBE-1 levels the control group was significantly lower than the other groups (p < 0.05). The values of the group given BA were lower between the IR group and the BA+IR group, this difference was not statistically significant. (p = 0.28) (Figure 1). When IMA levels between the 3 groups were compared no significant difference was found between the groups (p > 0.05).

When we look at the total antioxidant capacity (TAS) the antioxidant capacity of the group given BA was significantly higher (p = 0.02). When the total oxidant capacity (TOS) is examined all three groups were significantly different from each other (p = 0.0019). While the control group had the lowest TOS values the IR group had the highest TOS values. While TOS values of the group given BA were significantly higher than the control group it was significantly lower than that of the IR group.

Hepatic damage degree of IR group was higher than other groups (p < 0.001). There was no statistically significant difference between control group and BA+IR group for grade parameter (p = 0.36). There was no or minimal hepatic damage in the livers of rats in the control group (Figures 2 A and B). In the IR group loss of intercellular border loss in hepatocytes, diffuse nuclear pycnosis, and mild to moderate neutrophilic cell infiltration (grade 2) were observed (Figures 3A and B). Dissociation, hemorrhage, and severe neutrophilic cell infiltration in hepatocytes in rats with IR (grade 3) were seen (Figure 4A and B). Liver damage was minimal in rats given BA before IR (Figure 5A and B).

4. Discussion
Liver IR injury is common in complicated surgical procedures, major trauma, and transplantation cases. Although ways are sought to reduce this damage the
development of IR injury cannot be prevented. It is emphasized that antioxidant substances should be given before ischemia develops. Experimental studies are still ongoing because an effective method has not been found yet.

The most important finding in our study is that BA exerts a hepatoprotective effect on rats that we have experimentally developed IR injury of cholestatic liver. Both histopathological and biochemical results of this study showed better results in the BA given group compared to the control group in terms of liver function and tissue samples.

The liver has a serious blood flow to maintain many synthesis and secretion functions. Therefore, ischemia is very sensitive to reperfusion. Damage during reperfusion is divided into early and late periods. While cellular damage is seen 2–6 h after reperfusion in the early period neutrophil dominance is observed in the late period. While free oxygen radical-mediated damage is prominent in the early period neutrophil-mediated inflammatory response is dominant in the late period [20]. Another effective mechanism in IR injury is the impairment of intracellular Ca\(^{2+}\), Na\(^{+}\), H\(^{+}\) balances by decreasing mitochondrial ATP production. The intracellular increase of Ca\(^{2+}\) increase FOR production and triggers apoptotic mechanisms. Cholestasis is a clinical condition that occurs as a result of arrest or slowing of bile flow due to obstruction in intra or extrahepatic bile ducts. While cholestasis alone increases Kupffer cell activation and may cause FOR release. IR injury that develops in the presence of cholestasis is much more severe [21]. Many surgeons expect the pre-operative bilirubin levels to decrease in patients with very high bilirubin levels in elective operations.

| Table. Laboratory findings of study groups [the results were presented as median and 95% CI (confidence interval)]. |
|---------------------------------------------------------------|
| **GROUP I** | **GROUP II** | **GROUP III** | **P** | **P1** | **P2** | **P3** |
| SCUBE1* (ng/mL) | 12.27 (10.5–14.88) | 19.42 (15.96 – 23.64) | 17.17 (13.63–22.10) | <0.01 | <0.01 | 0.01 | 0.367 |
| TOS** (μmol H2O2 equiv./L) | 6.51 (4.63–17.49) | 29.48 (20.77–43.95) | 19.98 (13.11–29.85) | <0.01 | <0.01 | 0.02 | 0.104 |
| TAS*** (μmol Trolox equiv./L) | 2.47 (2.37–2.71) | 2.28 (2.12–2.67) | 3.29 (2.61–3.49) | <0.01 | 0.16 | 0.01 | <0.01 |
| OSI (TOS/TAS)* | 3.69 (1.89–6.51) | 12.99 (9.36–19.1) | 6.43 (3.76–9.62) | <0.01 | 0.01 | 0.02 | <0.01 |
| IMA (absorbance unit) | 0.875 (0.824–0.900) | 0.913 (0.867–0.924) | 0.920 (0.874–0.952) | 0.07 | 0.234 | 0.065 | 0.104 |
| Albumin* (g/dL) | 3.7 (3.5–3.9) | 2.75 (2.68–3.1) | 2.85 (2.52–3.1) | <0.01 | <0.01 | <0.01 | 0.995 |
| IMAR (IMA/Albumin)*** | 0.234 (0.223–0.24) | 0.325 (0.291–0.34) | 0.323 (0.291–0.37) | <0.01 | <0.01 | <0.01 | 0.699 |
| ALP* (U/L) | 108 (46.9–201.7) | 271 (210.5–393.7) | 250 (219.6–289.6) | <0.01 | <0.01 | <0.01 | 0.645 |
| ALT* (U/L) | 52 (45–56.1) | 141 (96.3–191) | 122 (97.7–226.3) | <0.01 | <0.01 | <0.01 | 0.959 |
| AST* (U/L) | 96 (72–133) | 568 (398–763) | 545 (405–763) | <0.01 | <0.01 | <0.01 | 0.999 |
| TBIL* (mg/dL) | 0.275 (0.24–0.34) | 10.08 (2.464–12.19) | 9.73 (2.28–11.09) | <0.01 | <0.01 | <0.01 | 0.505 |
| DBIL* (mg/dL) | 0.01 (0.008–0.02) | 6.4 (1.1–7.4) | 5.8 (0.991–7.1) | <0.01 | <0.01 | <0.01 | 0.507 |

**NOTE** = the values are presented as median (min-max). Values are given as median (95%CI). p – between three groups; p1 – between group-I and group-II; p2 – between group-I and group-III; p3 – between group-II and group III.
are fewer studies. This study was planned because BA has antioxidant effects and boron is a mineral found in our country.

Trace element boron which is the characteristic element of BA may have significant effects on various metabolic and physiological systems in organism [22].
The effects of BA on vitamin, enzyme, hormone, energy and mineral metabolism have been shown in some studies [11,23]. The researchers explain the biological effects of BA by two different hypotheses. In the first hypothesis it is argued that BA is negative regulator affecting the path of competitive inhibition in key enzyme reactions [24]. In the second hypothesis it is argued that BA plays an important role in cell membrane function, structure and stability [25].

In a study aimed to use BA as an antioxidant to protect liver from IR injury they found this beneficial effect probably originated from radical scavenging activity of BA [26]. In addition, BA pretreatment prevented ischemia induced alterations in liver tissue biomolecules. Supporting this, the protective effect of BA against liver damage induced by carbon tetrachloride (CCl4) was found in mice [27]. Besides, BA decreased inflammation, oxidative stress, and apoptosis caused by cisplatin toxicity and increased ER stress in kidney [28]. Sogut et al. indicated antioxidant and antiapoptotic effects of boric acid on hepatotoxicity in chronic alcohol fed rats [29]. In our study we found BA was seen to significantly reduce inflammation and fibrosis by examination of the liver tissue samples histopathologically. Besides, according to our findings BA increased the antioxidant capacity and decreased the oxidant capacity when TAS/TOS levels were examined. On the other hand, further studies need to focus on highlight the underlying these effects/mechanisms of BA protection.

IMA is an albumin that changes its structure as a result of ischemia. In addition to ischemia IMA may increase in acute coronary syndrome, cerebrovascular diseases, liver failure, end-stage renal disease, severe traumas, pulmonary embolism, sepsis, diabetes, systemic sclerosis, some neoplastic diseases, and infections [30–32]. In a study conducted with IMA in chronic liver disease. Forty-three individuals with chronic liver disease and...
28 healthy individuals were compared. IMA values were found to be significantly higher but AST and ALT albumin values did not correlate with these high IMA values. IMA was inversely proportional to albumin [33]. In a study conducted on 33 healthy children and 33 children with chronic liver disease, a correlation was found between fibrous scoring and IMA and no relationship was found with other biochemical parameters [34]. In a study in which an experimental acute mesenteric ischemia model was applied, although an increase was observed in IMA values at 0, 1, 3, and 6 h no significant difference was found [35]. In our study albumin values of the control group were high while the albumin values of the IR group and the group given BA were low. There was no statistically significant difference between these two groups. Although there was a difference in albumin values for 3 groups when IMA levels were compared no statistically significant difference was found between 3 groups.

Although there are many methods for evaluating parenchymal damage in liver IR injury the most frequently used measurements are serum AST, ALT, and LDH values [36]. When we looked at these values in our study we saw that the values of the group 1 were low while the IR group and BA group were high. When the IR group and the BA group were compared there was no statistically significant difference.

Cholestasis occurs in many situations in the clinic. The most common causes are gallstones and benign and malignant tumors. We followed the rats for 1 week after ligation of the common bile duct to induce experimental obstructive jaundice. In the case of cholestasis serum bilirubin levels and ALP levels are the most investigated parameters. When the groups were compared, total and direct bilirubin levels and ALP were lower in the control group while it was higher in the IR group and BA+IR group. There was no statistically significant difference between the IR and the BA+IR groups. The therapeutic effect of BA in the early period did not reflect to associated laboratory values for ALT/AST and bilirubin/ALP levels and as a result there is not a statistically significant difference was found between IR and IR-BA groups.
As a result of the activation of macrophages with reperfusion, pro-inflammatory cytokine release increases in the environment. In the studies of Başbuğ et al. proinflammatory cytokines IL-6 and TNF-α were found to be higher in the hepatic IR group but decreased in the BA group [46].

Malondialdehyde (MDA) levels increased and antioxidant reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) levels were found to be decreased in the gentamicin-induced oxidative stress experiment model in rats; in the group given BA it was shown that MDA levels decreased. GSH, SOD, and CAT levels increased [47]. In the ovarian IR experimental model, the administration of 2-aminoethoxydiphenylborate (2-APB) showed that the TAS level was higher and the TOS level was lower than the IR group [48]. In a study conducted. It was shown that BA increased GSH. SOD and CAT levels in formaldehyde-induced oxidative stress, decreased the level of MDA, and decreased the proinflammatory level of TNF-α [49]. In the experimental necrotizing enterocolitis model it has been shown that BA increases antioxidant mechanisms and decreases pro-inflammatory IL-6 and TNF-α [50].

2-aminoethoxydiphenylborate (2-ABP) one of the boron compounds is used in calcium channel stabilization. Increase in intracellular and mitochondrial calcium forms the basis of IR injury. In the literature, studies showing that IR damage can be reduced by inhibiting intracellular and microcrystalline calcium increase with 2-ABP in the hepatic IR model [51,52]. A limitation of our study is that although studies in large sample size and large animal models are needed to evaluate the effectiveness for the clinical application

In conclusion, to the best of our knowledge this is the first experimental study in literature to have examined the effect of BA on experimental IR injury of the cholestatic liver. Liver tissue samples were examined histopathologically and BA was seen to significantly reduce inflammation and fibrosis. Again when TAS/TOS levels were examined it was seen that BA increased the antioxidant capacity and decreased the oxidant capacity. Thus the results of the study demonstrated the hepatoprotective effect of intraperitoneal BA administration before IR injury of the cholestatic liver. Nevertheless, further experimental and clinical studies are needed to better understand the protective role and mechanism of BA.

Acknowledgement/Disclaimers/Conflict of interest

Funding

This research was funded by a grant from Antalya Training and Research Hospital.

Conflict of interest

The authors declare that they have no conflict of interest.
References

1. Lu TF, Yang TH, Zhong CP, Shen C, Lin WW et al. Dual effect of hepatic macrophages on liver ischemia and reperfusion injury during liver transplantation. Immune Network 2018; 18 (3): e24. doi: 10.4110/in.2018.18.e24

2. Nastos C, Kalimeris K, Papoutsidakis N, Tasoulis MK, Lykoudis PM et al. Global consequences of liver ischemia/reperfusion injury. Oxidative Medicine and Cellular Longevity 2014. doi: 10.1155/2014/90696

3. Aragno M, Cutrin JC, Mastrocola R, Perrelli MG, Restivo F et al. Oxidative stress and kidney dysfunction due to ischemia/reperfusion in rat: attenuation by dehydroepiandrosterone. Kidney International 2003; 64 (3): 836-843. doi: 10.1046/j.1523-1755.2003.00152.x

4. Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Reviews (Orlando) 2012; 26 (2): 103-114. doi: 10.1016/j.trre.2011.10.006

5. Kloek JJ, Marsman HA, Van Vliet AK, Gouma DJ, Van Gulik TM. Biliary drainage attenuates postsischemic reperfusion injury in the cholestatic rat liver. Surgery 2008; 144 (1): 22-31. doi: 10.1016/j.surg.2008.03.030

6. Yoshidome H, Miyazaki M, Shimizu H, Ito H, Nakagawa K et al. Obstructive jaundice impairs hepatic sinusoidal endothelial cell function and renders liver susceptible to hepatic ischemia/reperfusion injury. Journal of Hepatology 2000; 33 (1): 59-67. doi: 10.1016/s0168-8278(00)80160-9

7. Jaeschke H, Farhood A, Smith CW. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB Journal 1990; 4 (15): 3355-3359.

8. Datta G, Fuller BJ, Davidson BR. Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models. World Journal of Gastroenterology 2013; 19 (11): 1683-1698. doi: 10.3748/wjg.v19.i11.1683

9. Hunter, C. Boron. In Encyclopedia of Dietary Supplements. Edited by B.M. Coates PM, Cragg GM, Levine M, Moss J and White JD. Marcel Dekker, New York; 2005. pp. 55-65.

10. Nielsen FH. Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation. FASEB Journal 1991; 5 (12): 2661-2667.

11. Ince S, Kucukkurt I, Cigerci IH, Fatih Fidan A, Eryavuz A. The effects of dietary boron acid and borax supplementation on lipid peroxidation, antioxidant activity, and DNA damage in rats. Journal of Trace Elements in Medicine and Biology 2010; 24 (3): 161-164. doi: 10.1016/j.jtemb.2010.01.003

12. Türkez H, Geyikoglu F, Tatar A, Keles MS, Kaplan I. The effects of some boron compounds against heavy metal toxicity in human blood. Experimental and Toxicologic Pathology 2012; 64 (1-2): 93-101. doi: 10.1016/j.etp.2010.06.011

13. Türkez H, Geyikoglu F, Tatar A, Keles S, Ozkan A. Effects of some boron compounds on peripheral human blood. Zeitschrift fur Naturforschung. C, Journal of Biosciences 2007; 62 (11-12): 889-896. doi: 10.1515/znc-2007-11-1218

14. Colak S, Geyikoglu F, Keles ON, Türkez H, Topal A et al. The neuroprotective role of boric acid on aluminum chloride-induced neurotoxicity. Toxicology and Industrial Health 2011; 27 (8): 700-710. doi: 10.1177/0748233710395349

15. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. The Journal of Emergency Medicine 2000; 19 (4): 311-315. doi: 10.1016/s0736-4679(00)00255-9

16. Erel O. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 2005; 38 (12): 1103-1111. doi: 10.1016/j.clinbiochem.2005.08.008

17. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical Biochemistry 2004; 37 (4): 277-285. doi: 10.1016/j.clinbiochem.2003.11.015

18. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Medical Weekly 2003; 133 (41-42): 563-566.

19. Onder A, Kapan M, Gümüş M, Yüksel H, Böyük A et al. The protective effects of curcumin on intestine and remote organs against mesenteric ischemia/reperfusion injury. Turkish Journal of Gastroenterology 2012; 23 (2): 141-147. doi: 10.4318/tjg.2012.0446

20. Tapuria N, Junnarkar S, Abu-Amara M, Fuller B, Seifalian AM et al. Modulation of microcirculatory changes in the late phase of hepatic ischaemia-reperfusion injury by remote ischaemic preconditioning. HPB (Oxford) 2012; 14 (2): 87-97. doi: 10.1111/j.1477-2574.2011.00407.x

21. Çakır T, Aslaner A, Tekeli SÖ, Güneş K, Kinaci E et al. Grape seed protects cholestatic rats liver from ischemia/reperfusion injury. Acta Cirúrgica Brasileira 2016; 31 (3): 183-189. doi: 10.1590/S0102-86502016003000006

22. Khaflı H, Jumng Z, Ke-Mei P. The physiological role of boron on health. Biological Trace Element Research 2018; 186 (1): 31-51. doi: 10.1007/s12011-018-1284-3

23. Kar F, Hacioglu C, Senturk H, Donmez DB, Kanbak G. The role of oxidative stress, renal inflammation, and apoptosis in post ischemic reperfusion injury of kidney tissue: the protective effect of dose-dependent boric acid administration. Biological Trace Element Research 2020; 195 (1): 150-158. doi: 10.1007/s12011-019-01824-1

24. Hunt CD. The biochemical effects of physiologic amounts of dietary boron in animal nutrition models. Environmental Health Perspectives 1994; 102 (Suppl 7): 35-43. doi: 10.1289/ehp.94102s735

25. Nielsen FH. Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation. FASEB Journal 1991; 5 (12): 2661-2667.

26. Ozek NS, Y ardından BK, Yildirim S. Hepatoprotective role of boric acid supplementation on liver injury induced by renal ischemia-reperfusion. International Symposium on Affective Science and Engineering 2018, 2018, 26.
GÜLER et al. / Turk J Med Sci

27. Ince S, Keles H, Erdogan M, Hazman O, Kucukkurt I. Protective effect of boric acid against carbon tetrachloride-induced hepatotoxicity in mice. Drug and Chemical Toxicology 2012; 35 (3): 285-292. doi: 10.3109/01480545.2011.607825

28. Hazman Ö, Bozkurt MF, Fidan AE, Uysal FE, Çelik Ş. The effect of boric acid and borax on oxidative stress, inflammation, ER stress and apoptosis in cisplatin toxicity and nephrotoxicity developing as a result of toxicity. Inflammation 2018; 41 (3): 1032-1048. doi: 10.1007/s10753-018-0756-0

29. Sogut I, Olgakci A, Kartkaya K, Ol KK, Sogut MS et al. Effect of boric acid on oxidative stress in rats with fetal alcohol syndrome. Experimental and Therapeutic Medicine 2015; 9 (3): 1023-1027. doi: 10.3892/etm.2014.2164

30. Yin M, Liu X, Chen X, Li C, Qin W et al. Ischemia-modified albumin is a predictor of short-term mortality in patients with severe sepsis. Journal of Critical Care 2017; 37: 7-12. doi: 10.1016/j.jccr.2016.08.005

31. Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metabolism and Pharmacokinetics 2009; 24 (4): 333-341. doi: 10.2133/dmpk.24.333

32. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clinical Chemistry and Laboratory Medicine 2011; 49 (2): 177-184. doi: 10.1515/CCLM.2011.037

33. Kumar PA, Subramanian K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. Journal of Clinical and Diagnostic Research 2016; 27 (1): 61-67. doi: 10.1097/MPG.0b013e3182a7e02b

34. Cakır M, Karahan SC, Mentese A, Sag E, Cobanoglu U et al. Ischemia-modified albumin levels in children with chronic liver disease. Gut and Liver 2012; 6 (1): 92-97. doi: 10.5009/gnl.2012.6.1.92

35. Dundar ZD, Cander B, Gul M, Karabulut KU, Girisgin S. Serum ischemia-modified albumin levels in an experimental acute mesenteric ischemia model. Academic Emergency Medicine 2010; 17 (11): 1233-1238. doi: 10.1111/j.1553-2712.2010.09916.x

36. Aslaner A, Çakır T, Çelik B, Doğan U, Akyüz C et al. The protective effect of intraperitoneal medical ozone preconditioning and treatment on hepatotoxicity induced by methotrexate. International Journal of Clinical and Experimental Medicine 2015; 8 (8): 13303-13309

37. Lindemann S, Gawaz M. SCUBE1—a new scoop in vascular biology? Cardiovascular Research 2006; 71 (3): 414-415. doi: 10.1016/j.cardiores.2006.06.005

38. Dirican N, Duman A, Sağlam G, Arslan A, Oztruk O et al. The diagnostic significance of signal peptide-complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein-1 levels in pulmonary embolism. Annals of Thoracic Medicine 2016; 11 (4): 277-282. doi: 10.4103/1817-1737.191876

39. Dai DF, Thajeb P, Tu CF, Chiang FT, Chen CH et al. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. Journals of the American College of Cardiology 2008; 51 (22): 2173-2180. doi: 10.1016/j.jacc.2008.01.060

40. Türkmen S, Eryigit U, Karaca Y, Mentese A, Sumer UA et al. Diagnostic value of plasma signal peptide-Cub-Egf domain-containing protein-1 (SCUBE1) in an experimental model of acute ischemic stroke. The American Journal of Emergency Medicine 2015; 33 (2): 262-265. doi: 10.1016/j.ajem.2014.11.051

41. Türkmen S, Mentese S, Mentese A, Sumer AU, Sağlam K et al. The value of signal peptide-CUB-EGF domain-containing protein 1 and oxidative stress parameters in the diagnosis of acute mesenteric ischemia. Academic Emergency Medicine 2013; 20 (3): 257-264. doi: 10.1111/acem.12096

42. Ulusoy S, Ozkan G, Menteşe A, Yavuz A, Karahan SC et al. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level. Clinical Biochemistry 2012; 45 (16-17): 1444-1449. doi: 10.1016/j.clinbiochem.2012.07.103

43. Mentese A, Fidan E, Sumer AU, Karahan SC, Sonmez M et al. Is SCUBE 1 a new biomarker for gastric cancer? Cancer Biomarkers 2012; 11 (5): 191-195. doi: 10.3233/CBM-2012-00285

44. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. The American Journal of Physiology-Gastrointestinal and Liver Physiology 2003; 284 (1): G15-26. doi: 10.1152/ajpgi.00342.2002 PMID: 12488232.

45. Türköz H, Geyikoglu F, Çolak S. The protective effect of boric acid on aluminum-induced hepatotoxicity and genotoxicity in rats. Turkish Journal of Biology 2011; 35: 293-301 doi: 10.3906/biy-0902-11

46. Basbug M, Yildar RM, Yaman I, Ozkan OF, Aksit H et al. Effects of boric acid in an experimental rat model of hepatic ischemia-reperfusion injury. Acta Medica Mediterranea 2015; 31 (5): 1067-1073.

47. Kucukkurt I, Arslan-Acaroz D, Demirel HH, Ince S, Yavuz A. Potential protective effect of boron against gentamicin-induced oxidative stress on rat tissues Kocatepe Veterinary Journal 2017; 10 (3): 172-179.

48. Taskin MI, Hismiogullari AA, Yay A, Adali E, Gungor AC et al. Effect of 2-aminoethoxydiphenyl borate on ischemia-reperfusion injury in a rat ovary model. European Journal of Obstetrics & Gynecology and Reproductive Biology 2014; 178: 74-79. doi: 10.1016/j.ejogrb.2014.03.049

49. Arslan-Acaroz D, Bayşu-Sozbilir N. Ameliorative effect of boric acid against formaldehyde-induced oxidative stress in A549 cell lines. Environmental Science and Pollution Research 2020; 27 (4): 4067-4074. doi: 10.1007/s11356-019-06986-y

50. Yazıcı S, Akşıt H, Korkut O, Sunay B, Çelik T. Effects of boric acid and 2-aminoethoxydiphenylborate on necrotizing enterocolitis. Journal of Pediatric Gastroenterology and Nutrition 2014; 58 (1): 61-67. doi: 10.1097/MPG.0b013e3182a7e02b
51. Jiang N, Zhang ZM, Liu L, Zhang C, Zhang YL et al. Effects of \( Ca^{2+} \) channel blockers on store-operated \( Ca^{2+} \) channel currents of Kupffer cells after hepatic ischemia/reperfusion injury in rats. World Journal Gastroenterology 2006; 12 (29): 4694-4698. doi: 10.3748/wjg.v12.i29.4694

52. Nicoud IB, Knox CD, Jones CM, Anderson CD, Pierce JM et al. 2-APB protects against liver ischemia-reperfusion injury by reducing cellular and mitochondrial calcium uptake. American Journal of Physiology-Gastrointestinal and Liver Physiology 2007; 293 (3): 623-630. doi: 10.1152/ajpgi.00521.2006